期刊
RHEUMATOLOGY
卷 49, 期 6, 页码 1184-1188出版社
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keq062
关键词
Infliximab; Eosinophilic fasciitis; Case report; Case series; Anti-tumour necrosis factor antagonists
类别
资金
- National Institutes of Health [NIAMS K23 AR053858-03]
- Scleroderma Foundation
Objective. EF is a rare fibrosing disorder that may involve skin and internal organs. Current therapies include moderate-to high-dose glucocorticoids with or without use of immunosuppressives. Methods. We report three cases of steroid-resistant EF in clinical practice who were treated with 3 mg/kg every 8 weeks infliximab therapy. Results. All patients noticed an improvement in their symptoms, joint contractures and skin thickening within 8 weeks of starting infliximab therapy, ultimately leading to a drug-free remission (range 1-3 years). Conclusion. Based on this and other reported cases, infliximab may be beneficial in patients with steroid-resistant EF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据